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E-mail address: ohinata@kais.kyoto-u.ac.jp (K. OhiWe found that Tyr-Leu (YL) dose-dependently exhibits potent anxiolytic-like activity (0.1–1 mg/kg,
i.p.) comparable to diazepam in the elevated plus-maze test in mice. YL was orally active (0.3–
3 mg/kg). A retro-sequence peptide or a mixture of Tyr and Leu was inactive. The anxiolytic-like
activity of YL was inhibited by antagonists for serotonin 5-HT1A, dopamine D1 and GABAA receptors;
however, YL had no afﬁnity for them. We also determined the order of their activation is 5-HT1A, D1
and GABAA receptors using selective agonists and antagonists. Taken together, YL may exhibit anx-
iolytic-like activity via activation of 5-HT1A, D1 and GABAA receptors.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
It has been reported that low molecular weight peptides con-
sisting of 3–7 L-amino acids sometimes exhibit anxiolytic-like
activities after oral administration in behavioral pharmacological
tests in mice. A number of bioactive peptides have been isolated
from enzymatic digests of food proteins. Among them, rubisco-
lin-6 (YPLDLF), a d opioid peptide derived from the large subunit
of spinach d-ribulose-1,5-bisphosphate carboxylase/oxygenase
(Rubisco), showed anxiolytic-like activities at a dose of 100 mg/
kg after oral administration in the elevated plus-maze test in mice
[1,2]. Orally administered soymorphin-5, 6 and 7 (YPFVV, YPFVVN
and YPFVVNA, respectively), l opioid peptides derived from soy b-
conglycinin had anxiolytic-like activity at a dose of 10–30 mg/kg in
mice [3]. Rubimetide (MRW), a hypotensive and vasorelaxing tri-
peptide derived from Rubisco, exhibited anxiolytic-like activity at
a dose of 1 mg/kg after oral administration [4]. In the current
study, we found that tyrosyl leusine (YL) had potent anxiolytic-like
activity after oral administration at a lower dose than previouslychemical Societies. Published by E
nata).reported anxiolytic-like peptides [1–4]. We then investigated the
mechanism of the anxiolytic-like activity of YL.
It was known that serotonin 5-HT1A receptor, dopamine D1
receptor, and c-amino butyric acid type A (GABAA) receptor played
an important key role in anxiolytic-like activity [1,5–7]; therefore,
we tested whether the anxiolytic-like activity of YL is mediated by
activation of these receptors. Furthermore, we determined the or-
der of activation of 5-HT1A, D1 and GABAA receptors in anxiolytic-
like activity using agonists and antagonists for them.2. Materials and methods
2.1. Animals
Four–six-week-old male ddY mice at 20–24 g or 26–30 g body
weight for intracerebroventricular (i.c.v.) or intraperitoneal (i.p.)
and oral (p.o.) administration, respectively, were obtained from
SLC (Shizuoka, Japan). Seven-week-old mice were also used for
i.p. administration. All animals were housed in a temperature-con-
trolled room (23 C) on a 12-h light–dark cycle with lights on at
07:00. All animals had free access to food pellets and water. All
experiments were approved by the Kyoto University Ethics Com-
mittee for Animal Research Use. All animals were euthanized by
an overdose of anesthesia drugs after the experiment.lsevier B.V. All rights reserved.
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Fig. 1. Anxiolytic-like activity of YL after i.p. administration in the elevated plus-
maze test in mice. YL at a dose of 0.03–1 mg/kg was i.p. administered 30 min before
the tests. The percentages of time (A) and visits (B) spent in the open arms, and total
visits (C) to both open and closed arms during the test for 5 min were measured.
Each value is expressed as the means ± S.E.M. (n = 5–8). *P < 0.05, **P < 0.01,
compared with the saline-treated control group.
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Tyr-Leu (YL), Tyr-Ile (YI), Leu-Tyr (LY), Ile-Tyr (IY) and Leu-Tyr-
Leu (LYL) were obtained from Bachem AG (Bufendorf, Switzerland).
Tyr-Leu-Tyr (YLY) and Tyr-Leu-Gln (YLQ) were synthesized by
F-moc strategy. Amino acids Tyr and Lue were purchased from
Wako Pure Chemical Industries Ltd. (Osaka, Japan). WAY100135
dihydrochloride, a serotonin 5-HT1A receptor antagonist; R(+)-
SCH-23390 hydrochloride, a dopamine D1 receptor antagonist;
()-bicuculline, c-amino butyric acid (GABA)A receptor antagonist;
8-hydroxy-DPAT hydrobromide, a serotonin 5-HT1A receptor ago-
nist; SKF38393, a dopamine D1 receptor agonist; were obtained
from Tocris Bioscience (Bristol, UK). Muscimol, a GABAA receptor
agonist, and diazepam were purchased from Sigma–Aldrich Inc.
(St. Louis, MO).
2.3. Elevated plus-maze test
Anxiolytic-like behavior was measured using the elevated plus-
maze (EPM) test, which was performed as described previously
[1,3,4,8–10]. Four arms (25 cm long  5 cm wide) were placed
50 cm above the ground. Two opposite arms were delimited by ac-
rylic vertical walls (15 cm high, closed arms), whereas the other
two, opposite arms had unprotected edges (open arms). A mouse
was placed in the center of the maze facing an open arm and ob-
served for 5 min to measure the cumulative time and frequency
of entries into open and closed arms. Arm entry was deﬁned as
the entry of four paws into an arm. Open-arm entry time (time
spent in open arms) was expressed as a percentage of the total en-
try time (% of time), and the number of open-arm entries was ex-
pressed as a percentage of the number of total entries (% of visit).
Peptides or amino acids dissolved in saline were i.p. administered
30 min before the test. Diazepam was also dissolved in saline by
sonication. Antagonists were i.p. co-administered with peptide
30 min before the test. YL in saline was also administered by ga-
vage. The total number of visits to open and closed arms, and the
cumulative time spent in open and closed arms were measured
on a monitor through a video camera system. The data were
checked by observers unaware of the experimental groups. The
EPM test was started at 11:00 a.m. during the light phase of the
light/dark cycle.
2.4. Open-ﬁeld test
The open-ﬁeld test was performed as previously described with
slight modiﬁcation [11]. The apparatus consisted of a circular arena
of 60 cm diameter and wall height of 50 cm. The apparatus was
gray with black lines on the bottom, which divided the open-ﬁeld
into 25 parts of similar area by two concentric circles as a series of
radii. Each mouse was placed in the center circle and its movement
monitored through a video camera system for 5 min. The time
spent in the center circle was measured. The open-ﬁeld test was
started at 11:00 a.m.
2.5. Intracerebroventricular (i.c.v.) administration
I.c.v. administration was performed as described previously
[12–14]. Brieﬂy, a 28-gauge stainless steel needle attached to a
0.05-ml Hamilton syringe was inserted perpendicularly through
the skull into the brain. The site of injection was 2 mm from either
side of the midline on a line drawn through the anterior base of
the ears (the lateral ventricle). YL was dissolved in artiﬁcial cere-
brospinal ﬂuid (ACSF: 138.9 mM NaCl, 3.4 mM KCl, 1.3 mM CaCl2,
4.0 mM NaHCO3, 0.6 mM NaH2PO4, 5.6 mM glucose, pH 7.4). Four
microliters of YL solution was i.c.v. administered 20 min before
the test.2.6. Statistical analysis
All values are expressed as the means ± S.E.M. Analysis of vari-
ance (ANOVA) followed by Fisher’s test was used to assess differ-
ences among groups. P values less than 0.05 were considered
signiﬁcant.
3. Results
3.1. Dipeptide YL exhibits potent anxiolytic-like activity after oral
administration
We tested whether dipeptide YL and its related peptides exhib-
ited anxiolytic-like activity after i.p. administration in the elevated
plus-maze test and open-ﬁeld test in mice. Initially we investigated
anxiolytic-like activity of Ile-Tyr (IY), which is an ACE inhibitory
peptide with anti-hypertensive activity, since ACE inhibitors some-
times show anxiolytic-like activity [15]. IY at a dose of 30 mg/kg
exhibited anxiolytic-like activity after i.p. administration in the
elevated-plus maze test in mice (Supplementary Fig. S1). After pre-
liminary experiments using IY analogues, we ﬁnally found that YL
has anxiolytic-like activity at a lower dose than the minimum
effective dose of IY.
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Fig. 2. Comparison of the anxiolytic-like activities of YL, its derivatives and
diazepam. They were i.p. administered 30 min before the tests. The anxiolytic-like
activities induced by diazepam (A, 1 mg/kg), Tyr alone or a mixture of the
constitutive amino acids Tyr and Leu (B, 3.4 lmol/kg equimolar to 1 mg/kg of YL),
YL-related dipeptides (C), or tripeptides (D, 0.1–1 mg/kg) were measured in the
elevated plus-maze test in mice. Each value is expressed as the means ± S.E.M. (A,
n = 12; B, n = 5; C, n = 3–8; D, n = 3–9). *P < 0.05, **P < 0.01, ***P < 0.001, compared
with each group.
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dently increased the percentage of the time and visits in open arms
for 5 min in the elevated plus-maze test using ﬁve–six-week-old
mice at 26–30 g, but had no signiﬁcant effect on total entry num-
ber (Fig. 1). Seven-week-old mice at 34–36 g also showed anxio-
lytic-like activity after i.p. administration of YL (Supplementary
Fig. S2). In the open-ﬁeld test, YL at a dose of 0.1 mg/kg (i.p.) in-
creased time spent and visits in the center circle; however, loco-
motor activity was not affected (Table 1). Thus, we demonstrated
that YL exhibits anxiolytic-like activity after i.p. administration
by two paradigms. The minimum effective dose of YL in the ele-
vated plus-maze test was 0.1 mg/kg, which was comparable to
the anxiolytic. Indeed, the anxiolytic-like activity of YL tended to
be more potent than that of diazepam, a representative anxiolytic,
compared at the same doses (1 mg/kg, i.p.), as shown in Fig. 2A. A
mixture of constitutive amino acids Tyr and Leu at a dose of
3.4 lmol/kg equal mole to 1 mg/kg of YL was inactive (Fig. 2B).
LY, a retro-sequence dipeptide of YL, at a dose of 0.1–1 mg/kg
was also inactive (Fig. 2C), suggesting that the amino acid sequence
of YL is important for potent anxiolytic-like activity. YI, a dipeptide
with substitution of the branch chain amino acid Leu in YL for Ile,
and IY, its retro-sequence peptide, were also inactive at a dose of
0.1–1 mg/kg (Fig. 2C). The ACE inhibitory activity of YL
(IC50 = 109 lM) was lower than that of IY (IC50 = 3.4 lM), suggest-
ing that the anxiolytic-like activity of YL is independent of ACE
inhibitory activity.
For tripeptides containing the YL sequence, YLY and YLQ (0.3–
1 mg/kg, i.p.) had anxiolytic-like activity; however, LYL was inac-
tive (Fig. 2D). Taken together, the N-terminal site of YL may be
quite important for anxiolytic-like activity, and its C-terminal elon-
gation might be tolerated.
Orally administered YL (0.3–3.0 mg/kg equal to 1.0–10 lmol/
kg) increased the percentage of time in open arms of the maze
(Fig. 3A). Furthermore, centrally administered YL (0.1 nmol/mouse)
had anxiolytic-like activity (Fig. 3B). YL did not change the total
visits after oral and i.c.v. administration (data not shown), indicat-
ing that YL did not affect locomotor activity. Thus, we demon-
strated that orally administered YL has potent anxiolytic-like
activity in mice.
3.2. Anxiolytic-like activity of YL was mediated via activation of
serotonin 5-HT1A, dopamine D1 and GABAA receptors
We investigated the mechanism underlying the anxiolytic-like
activity of YL. 5-HT1A, D1 and GABAA receptors are known to be
associated with anxiolytic-like activity in animals and humans
[1,5–7]; thus, we investigated whether these receptors were in-
volved in the anxiolytic-like activity of YL using antagonists for
them.
The anxiolytic-like activity of YL (1 mg/kg, i.p.) was signiﬁ-
cantly blocked by i.p. pretreatment of WAY100135 (10 mg/kg),
SCH23390 (30 lg/kg), bicuculline (5 mg/kg) or ﬂumazenil (1 mg/
kg), an antagonist for 5-HT1A receptor, D1 receptor, the GABA site
of GABAA receptor or its benzodiazepine site, respectively (Fig. 4).
No antagonists used in this study had any effect on anxiety-re-Table 1
Anxiolytic-like activity of YL in open-ﬁeld behaviors.
Saline YL
% of time in center circle 0.889 ± 0.318 2.06 ± 0.234*
% of visits in center circle 1.53 ± 0.428 3.02 ± 0.404*
Locomoter activity 187 ± 13.4 189 ± 22.2
Results are expressed as the means ± S.E.M. (n = 6).
* P < 0.05, compared with the saline-treated control group.lated behavior in the elevated plus-maze test under our experi-
mental conditions (Fig. 4B and Supplementary Fig. S3). These
results suggest that the anxiolytic-like activity of YL is mediated
by 5-HT1A, D1 and GABAA receptors. Furthermore, the afﬁnity of
YL for 5-HT1A and D1 receptors, and GABA or benzodiazepine sites
of GABAA receptor at 100 lM were negligible (Supplementary
Table S1). These results suggest that YL exhibits anxiolytic-like
activity via the release of neurotransmitters, including serotonin,
dopamine and GABA, and the activation of 5-HT1A, D1 and GABAA
receptors.
3.3. Novel anxiolytic pathway via 5-HT1A, D1 and GABAA receptors
We investigated how these receptors were activated in emo-
tional regulation using agonists and antagonists selective for them.
The increase in the % of time in open arms by 8-OH-DPAT (1 mg/kg,
i.p.), an agonist for 5-HT1A receptor, was blocked by SCH23390 or
bicuculline, an antagonist for D1 or GABAA receptors, respectively
(Fig. 5A). The anxiolytic-like activity of SKF38393 (1 mg/kg, i.p.),
an agonist for D1 receptor, was inhibited by bicuculline, but not
by WAY100135 (Fig. 5B). The anxiolytic-like activity of muscimol
(0.3 mg/kg, i.p.), an agonist for GABAA receptor, was inhibited by
neither WAY100135 nor SCH23390 (Fig. 5C). Taken together, 5-
HT1A receptor activation may induce dopamine release and D1
receptor activation followed by GABA release and GABAA receptor
activation, probably in the central nervous system (CNS). Thus, we
hypothesized that YL induced serotonin release and 5-HT1A recep-
tor activation followed by the activation of D1 and GABAA recep-
tors, as shown in Fig. 5D.
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We found for the ﬁrst time that dipeptide YL had potent anxio-
lytic-like activity comparable to diazepam in the elevated plus-
maze test in mice. The amino acid sequence of YL was essential
for potent anxiolytic-like activity. YL was orally active, and the
minimum effective dose for anxiolytic-like activity after oral
administration (0.3 mg/kg) was threefold higher than that after
i.p. administration (0.1 mg/kg). The constitutive amino acid mix-
ture was inactive. The anxiolytic-like activity after oral administra-
tion might be explained by resistance to digestive protease in the
gastrointestinal tract as well as the low molecular weight. Cen-
trally administered YL also exhibited anxiolytic-like activity at a
dose of 0.1 nmol/mouse. This minimum effective dose after i.c.v.
administration was two orders of magnitude smaller than that
after i.p. administration (0.1 mg/kg equals to roughly 10 nmol/
mouse), suggesting that its site of action might be the CNS. Further
investigation will elucidate how dipeptide absorbed across the gas-
trointestinal tract and blood brain barrier (BBB) contributes to its
anxiolytic-like activity.
We also investigated the mechanism underlying the anxiolytic-
like activity of YL. This anxiolytic-like activity was blocked by
antagonists for 5-HT1A, D1 and GABAA receptors; however, YL had
no afﬁnity for them. Thus we found that the anxiolytic-like activity
of YL was mediated by the activation of 5-HT1A, D1 and GABAA
receptors, but not by acting as an agonist of each receptor. The re-
sults of the structure-activity relationship study shown in Fig. 2
permit us to speculate that the unidentiﬁed YL receptor may bind
to the N-terminus of YL and be activated, upstream of 5-HT1A, D1
and GABAA receptors. By pharmacological experiments using
agonists and antagonists, we also determined that the order ofactivation was 5-HT1A, D1 and GABAA receptors. Thus, we hypoth-
esized that the anxiolytic-like activity of YL was mediated as fol-
lows: YL? serotonin release? 5-HT1A receptor? dopamine
release? D1 receptor? GABA release? GABAA receptor? anxio-
lytic-like activity. In addition, the possibility that YL exhibits anx-
iolytic-like activity via an enzyme inhibition-dependent
mechanism in the CNS could not be ruled out.
It has been reported that a 5-HT1A receptor agonist exhibits
anxiolytic-like and antidepressant-like effects [16,17]. The 5-HT1A
receptor-knockout mice showed increased anxiety-like behavior
[18,19]. 5-HT1A receptors are localized not only in the serotonergic
cell bodies of the raphe nuclei but also in non-serotonergic neurons
in various brain regions, including the hippocampus, prefrontal
cortex and ventral tegmental area (VTA) [20].
D1 receptor agonist exhibited anxiolytic-like activity in previous
and our studies, and mice lacking D1 receptor showed anxiogenic
behavior [1,6], suggesting that D1 activation may decrease anxiety
in mice. The mesocorticolimbic pathway with dopaminergic pro-
jection from the VTA to frontal cortex and/or nucleus accumbens
is implicated in emotional and cognitive regulation, and the nigro-
striatal pathway from the substantia nigra to the striatum is in-
volved in motor function [21]. It was reported that systemic
administration of 5-HT1A agonist facilitated dopamine release in
the frontal cortex or nucleus accumbems [20].
GABAA receptor is also well-known to be associated with anxio-
lytic-like behavior, and is a chloride channel composed of a penta-
meric heterooligometric protein with binding sites for GABA,
benzodiazepines (BZD), barbiturates, steroids, etc. The BZD site is
located on the a subunit, while the GABA binding site is on the
b-subunit. The activation of the GABAA receptor induced by BZD
including diazepam reduces anxiety, whereas the c2 subtype of
GABAA receptor-knockout mice show increase anxiety [7,22,23].
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bovine as1-casein with afﬁnity for the BZD site, exhibits anxiolytic-
like activity after i.p. administration in rats. In contrast, YL did not
have afﬁnity for either BDZ or GABA sites of the GABAA receptor.
The anxiolytic-like activity of YL was blocked by antagonists for
both binding sites. Taken together, YL might show an anxiolytic-
like effect after activating the GABA binding site, probably by stim-
ulating presynaptic GABA release. Further investigation will eluci-
date where 5-HT1A, D1 and GABAA receptors in the CNS are
activated after YL administration.
Among a number of bioactive peptides isolated from the enzy-
matic digest of food proteins, several short peptides exhibited anx-
iolytic-like activity after oral administration. We reported that
soymorphin-5 (YPFVV) and rubiscolin-6 (YPLDLF), which are l and
d opioid peptides derived from soy b-conglycinin and spinach Rubi-
sco, respectively, had anxiolytic-like activities [1,3]. Rubiscolin-6
exhibits anxiolytic activity by activating r1 receptor, downstream
of d opioid receptor [3]; however, YL-inducedanxiolytic-like activity
was not blocked by antagonists for l and d opioid receptors and r1
receptor, naloxone, naltrindole and BMY14802, respectively (Sup-
plementary Fig. S4A and B), suggesting that YL shows anxiolytic-like
activity independently of these opioid systems. We have also re-
ported that rubimetide (MRW) derived fromRubisco exhibited anx-
iolytic-like activities via activation of the prostaglandin (PG) D2system, which is a novel anxiolytic pathway [4,8]. The anxiolytic-
like activity of YLwas not signiﬁcantly attenuated by a cyclooxygen-
ase inhibitor, indomethacin (Supplementary Fig. S4C), suggesting
that YL might be independent of the PG D2 system.
YL sequences are present in the primary structure of many
endogenous and exogenous proteins, including serum albumin
and natural food proteins such as milk and soy beans. Tripeptides
having a YL sequence in the N-termini maintain anxiolytic-like
activities. In addition, YLYEIAR, a serum albumin-derived hepta-
peptide having a YL sequence in the N-terminus also exhibited
anxiolytic-like activity (unpublished observation). These results
might not rule out the possibility that food protein-derived pep-
tides having a YL sequence after digestion by enzymes present in
the gastrointestinal tract potentially contribute to anxiolytic-like
activity in the post-prandial state.
In conclusion, YL had anxiolytic-like activity in the elevated
plus-maze test after i.p. (0.1 mg/kg) or oral (0.3 mg/kg) administra-
tion in mice, and this effect was blocked by antagonists for 5-HT1A,
D1 and GABAA receptors; however, YL had no afﬁnity for them. We
determined the order of activation of 5-HT1A, D1 and GABAA recep-
tors in anxiolytic-like activity using agonists and antagonists for
them. The anxiolytic-like activity of YL was mediated by the activa-
tion of 5-HT1A and dopamine D1 receptor followed by GABAA
receptor.
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